tiprankstipranks
Jaguar Animal Health (JAGX)
NASDAQ:JAGX

Jaguar Animal Health (JAGX) Stock Price & Analysis

2,156 Followers

JAGX Stock Chart & Stats

Day’s Range$0.17 - $0.19
52-Week Range― - ―
Previous Close$0.17
Volume44.00M
Average Volume (3M)N/A
Market Cap
$46.40M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
May 13, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

3.10%0.12%0.12%96.66%
0.12% Other Institutional Investors
96.66% Public Companies and Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

JAGX FAQ

What was Jaguar Animal Health’s price range in the past 12 months?
Currently, no data Available
What is Jaguar Animal Health’s market cap?
Currently, no data Available
When is Jaguar Animal Health’s upcoming earnings report date?
Jaguar Animal Health’s upcoming earnings report date is May 13, 2024 which is in 15 days.
    How were Jaguar Animal Health’s earnings last quarter?
    Jaguar Animal Health released its earnings results on Apr 01, 2024. The company reported $1.4 earnings per share for the quarter, beating the consensus estimate of N/A by $1.4.
      Is Jaguar Animal Health overvalued?
      According to Wall Street analysts Jaguar Animal Health’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Jaguar Animal Health pay dividends?
        Jaguar Animal Health does not currently pay dividends.
        What is Jaguar Animal Health’s EPS estimate?
        Jaguar Animal Health’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Jaguar Animal Health have?
        Currently, no data Available
        What happened to Jaguar Animal Health’s price movement after its last earnings report?
        Jaguar Animal Health reported an EPS of $1.4 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -11.111%.
          Which hedge fund is a major shareholder of Jaguar Animal Health?
          Currently, no hedge funds are holding shares in JAGX
          ---

          Company Description

          Jaguar Animal Health

          Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
          ---

          JAGX Earnings Call

          Q4 2024
          0:00 / 0:00
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          Petmed Express
          Zoetis
          Idexx Laboratories
          Elanco Animal Health
          Popular Stocks
          ---
          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis